Veterinary Research Forum
Vet Res Forum

Curcumin alleviates inflammatory effects of ketamine anesthesia in postnatal rats

Document Type : Original Article

Authors

Soroush Afshar Ghahremani 1
Abbas Raisi 1
Sohrab Minaei Beirami 2, 3
Houman Kahroba 4
Mahnaz Mardani 5
Omid Dezfoulian 6
Vahideh Tarhriz 7

1 Department of Clinical Sciences, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran

2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

3 Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

4 Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

5 Department of Health and Nutrition, Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

6 Department of Pathobiology, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran

7 Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, USA

https://doi.org/10.30466/vrf.2024.2018359.4107
Abstract
Curcumin has been employed in traditional medicine for over a millennium to treat various ailments, and its global use is now widespread. Chinese medicine relies heavily on curcumin as a primary element and uses it to cure infectious diseases, skin disorders, depression, and stress. It has cardioprotective, neuroprotective, and anti-diabetic properties, as well as pharmacological effects on disorders like type II diabetes, atherosclerosis, and human immunodeficiency virus replication. The anti-cancer activity of curcumin has been studied extensively with notable improvements in gastrointestinal, melanoma, urogenital, breast, and lung malignancies. We investigated the anti-inflammatory effects of curcumin on expression of tumor necrosis factor (TNF)-α, c-Fos, and interleukin (IL)-6 genes in brain and liver tissue owing to the effects of ketamine anesthesia on postnatal rats. The thalamic and hepatic tissues were collected without anesthesia, immediately after anesthesia, and 4 and 12 hr after anesthesia in control and curcumin treated postnatal rats. The results showed that glucose, triglyceride, high- and low-density lipoprotein levels were lowered with curcumin treatment. We also found that ketamine increased c-Fos and inflammatory cytokines like TNF-α and IL-6, all of which contribute to inflammation. Brain and liver immunohistochemistry studies confirmed the real-time polymerase chain reaction findings. Curcumin injections alone may be effective in decreasing ketamine-induced inflammation in both brain and liver tissues.

Keywords

Brain
Curcumin
Ketamine
Liver
Real-time polymerase chain reaction

Subjects

  1. Asgharian P, Quispe C, Herrera-Bravo J, et al. Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: an update. Front pharmacol 2022; 13: 926607. doi: 10.3389/fphar.2022.926607.
  2. Kolev TM, Velcheva EA, Stamboliyska BA, et al. DFT and experimental studies of the structure and vibrational spectra of curcumin. Int J Quantum Chem 2005; 102(6): 1069-1079.
  3. Lopresti AL, Smith SJ, Rea A, et al. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study. BMC Complement Med Ther 2021; 21(1): 40. doi: 10.1186/s12906-021-03220-6.
  4. Huang MT, Lysz T, Ferraro T, et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51(3): 813-819.
  5. Kulkarni AP, Ghebremariam YT, Kotwal GJ. Curcumin inhibits the classical and the alternate pathways of complement activation. Ann N Y Acad Sci 2005; 1056: 100-112.
  6. Chandra D, Gupta SS. Anti-inflammatory and anti-arthritic activity of volatile oil of Curcuma longa (Haldi). Indian J Med Res 1972; 60(1): 138-142.
  7. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50(11): 2191-2193.
  8. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15(12): 1867-1876.
  9. Tarhriz V, Yari Khosroushahi A, Ebrahimi Ghasor L, et al. Effect of essential oils of Zingiber officinale, Cinnamomum verum, Trachyspermum ammi, Cuminum cyminum, and Carum carvi on bacteria inducing clonal dysbiosis in vitro [Persian]. J Mazandaran Univ Med Sci 2021; 31(201): 16-27.
  10. Maleki Dizaj S, Sharifi S, Tavakoli F, et al. Curcumin-loaded silica nanoparticles: applications in infectious disease and food industry. Nanomaterials (Basel) 2022; 12(16): 2848. doi: 10.3390/nano12162848.
  11. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospho-lipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004; 25(9): 1671-1679.
  12. Liu Y, Hong XQ. Effect of three different curcumin pigmens on the prdiferation of vascular smooth muscle cells by ox-LDL and the expression of LDL-R [Chinese]. Zhongguo Zhong Yao Za Zhi 2006; 31(6): 500-503.
  13. Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheo-chromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 2001; 303(1): 57-61
  14. Nishiyama T, Mae T, Kishida H, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005; 53(4): 959-963.
  15. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005; 223(2): 181-190.
  16. Anand P, Sundaram C, Jhurani S, et al. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267(1): 133-164.
  17. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010; 17(3): 190-197.
  18. Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res 2014; 8(3): 283-290.
  19. Morgan CJ, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction 2012; 107(1): 27-38.
  20. Lynch ME, Clark AJ, Sawynok J, et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain 2005; 6(10): 644-649.
  21. Correll GE, Maleki J, Gracely EJ, et al. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med 2004; 5(3): 263-275.
  22. Takahashi T, Kinoshita M, Shono S, et al. The effect of ketamine anesthesia on the immune function of mice with postoperative septicemia. Anesth Analg 2010; 111(4): 1051-1058.
  23. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am J Emerg Med 2008; 26(9): 985-1028.
  24. Zou X, Patterson TA, Divine RL, et al. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci 2009; 27(7): 727-731.
  25. Yeung L, Wai MS, Fan M, et al. Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine. Toxicol Lett 2010; 193(2): 189-193.
  26. Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharmacol Sin 2016; 37(7): 865-872.
  27. Song JW, Shim JK, Song Y, et al. Effect of ketamine as an adjunct to intravenous patient-controlled analgesia, in patients at high risk of postoperative nausea and vomiting undergoing lumbar spinal surgery. Br J Anaesth 2013; 111(4): 630-635.
  28. Li Y, Shen R, Wen G, et al. Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration. Front Pharmacol 2017; 8: 139. doi: 10.3389/fphar.2017.00139.
  29. Gagea-Iurascu M, Craig S. The laboratory rabbit, guinea pig, hamster, and other rodents. 1st ed. London, UK: Academic Press 2012; 117-139.
  30. Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother 2010; 1(2): 94-99.
  31. Tarhriz V, Eyvazi S, Musavi M, et al. Transient induction of Cdk9 in the early stage of differentiation is critical for myogenesis. J Cell Biochem 2019; 120(11): 18854-18861.
  32. Forouhandeh H, Tarhriz V, Zadehkamand M, et al. Anti-proliferative activity of Artemisia marschalliana on cancerous cell lines. BMC Complement Med Ther 2023; 23(1): 119. doi: 10.1186/s12906-023-03887-z.
  33. Farjami A, Siahi-Shadbad M, Akbarzadehlaleh P, et al. Evaluation of the physicochemical and biological stability of cetuximab under various stress condition. J Pharm Pharm Sci 2019; 22(1): 171-190.
  34. Liu JR, Liu Q, Li J, et al. Noxious stimulation attenuates ketamine-induced neuroapoptosis in the developing rat brain. Anesthesiology 2012; 117(1): 64-71.
  35. Farjami A, Akbarzadehlaleh P, Molavi O, et al. Stability-indicating size exclusion chromatography method for the analysis of IgG mAb-cetuximab. Chromatographia 2019; 82(10): 767-776.
  36. Lee WC, Wu CC, Chuang YC, et al. Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate cyclophos-phamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder. J Ethno- pharmacol 2016; 184: 1-9.
  37. Charles P, Elliott MJ, Davis D, et al. Regulation of cyto kines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163(3): 1521-1528.
  38. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61(6): 588-602.
  39. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072(2-3): 129-157.
  40. Lee WC, Tain YL, Chuang YC, et al. Ba‐Wei‐Die‐Huang ‐Wan (Hachimi‐jio‐gan) can ameliorate ketamine‐ induced cystitis by modulating neuroreceptors, inflammatory mediators, and fibrogenesis in a rat model. Neurourol Urodyn 2019; 38(8): 2159-2169.
  41. Monajjemzadeh F, Farjami A. Common problems in stress testing of pharmaceutical preparations. J Mol Pharm Org Process Res 2014; 2(3): e117. doi: 10.4172/2329-9053.1000e117.
  42. Baj T, Seth R. Role of curcumin in regulation of TNF-α mediated brain inflammatory responses. Recent Pat Inflamm Allergy Drug Discov 2018; 12(1): 69-77.
  43. Xiao L, Ding M, Fernandez A, et al. Curcumin alleviates lumbar radiculopathy by reducing neuroinflammation, oxidative stress and nociceptive factors. Eur Cell Mater 2017; 33: 279-293.
  44. Moghaddam AH, Maboudi K, Bavaghar B, et al. Neuro-protective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neurosci Lett 2021; 765: 136249. doi: 10.1016/j.neulet.2021.136249.
  45. Pavlovic S, Jovic Z, Karan R, et al. Modulatory effect of curcumin on ketamine-induced toxicity in rat thymocytes: involvement of reactive oxygen species (ROS) and the phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt) pathway. Bosn J Basic Med Sci 2018; 18(4): 320-327.
Veterinary Research Forum
Volume 15, Issue 9
September 2024
Pages 473-480

  • Receive Date 20 December 2023
  • Revise Date 28 January 2024
  • Accept Date 05 February 2024

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us